NASDAQ : ACRS
Aclaris Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.97 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 615.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 602.12M |
| Enterprise Value | 433.34M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 154.98M |
| Shares Outstanding | 154.98M |
| Shares Change (YoY) | +25.53% |
| Shares Change (QoQ) | +10.81% |
| Owned by Insiders (%) | 2.10% |
| Owned by Institutions (%) | 52.41% |
| Float | 108.96M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 72.79 |
| Forward PS | 118.92 |
| PB Ratio | 4.46 |
| P/TBV Ratio | 4.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 52.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.46 |
| Quick Ratio | 3.46 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -59.10% |
| Return on Assets (ROA) | -28.98% |
| Return on Invested Capital (ROIC) | -41.03% |
| Return on Capital Employed (ROCE) | -56.46% |
| Weighted Average Cost of Capital (WACC) | 9.07% |
| Revenue Per Employee | $112,589 |
| Profits Per Employee | -$1.04M |
| Employee Count | 73 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +54.17% |
| 50-Day Moving Average | 4.83 |
| 200-Day Moving Average | 4.54 |
| Relative Strength Index (RSI) | 43.47 |
| Average Volume (20 Days) | 3,492,266 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 15.03M |
| Short Previous Month | 18.19M |
| Short % of Shares Out | 9.70% |
| Short % of Float | 13.79% |
| Short Ratio (days to cover) | 3.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 8.22M |
| Gross Profit | -62.28M |
| Operating Income | -85.51M |
| Pretax Income | -75.74M |
| Net Income | -75.74M |
| EBITDA | -85.53M |
| EBIT | -85.51M |
| Loss Per Share | -$0.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 91.56M |
| Total Debt | 1.85M |
| Net Cash | 168.77M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 124.58M |
| Book Value Per Share | 0.89 |
| Working Capital | 69.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -62.06M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | -12,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -62.18M |
| FCF Per Share | -$0.40 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,040.43% |
| Pretax Margin | -921.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -25.53% |
| Shareholder Yield | -25.53% |
| Earnings Yield | -15.09% |
| FCF Yield | -10.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.36 |
| Price Target Difference | 166.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | -9.82% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.91 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |